Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atorvastatin in Chronic Migraine (StainMigChronic)
2022-502177-42-02Phase 2Authorised
- Sponsor
- St. Olavs University Hospital
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, triple-blind trial in chronic migraine comparing atorvastatin 40 mg daily with placebo (2 arms). Primary endpoint: Change from baseline in number of migraine days per 4 weeks. Planned start Jun 2023; status: authorised.
02
Drugs
atorvastatin
03
Conditions
chronic migraine
Beyond the preview
Go deeper on 2022-502177-42-02.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502177-42-02.